AUTOINFLAMMATORY DISEASES IN CHILDREN(The Lecture from 18th of September 2013, Conference «Topical Problems of Diagnostics and Treatment of Juvenile Rheumatoid Arthritis» (18–20 of September, 2013, St. Petersburg))
https://doi.org/10.15690/vsp.v13i2.973
Abstract
Data about clinical signs, diagnostics and treatment of hereditary autoinflammatory syndromes, e.g. cryopyrin-associated periodic syndrome (CAPS), familial Mediterranean fever (FMF), TNF-receptor associated periodic syndrome (TRAPS-syndrome), hyperimmunoglobulinemia D syndrome (HIDS), Pyogenic Sterile Arthritis, Pyoderma Gangrenosum and Acne (PAPA) syndrome, juvenile sarcoidosis (Blau-syndrome) are shown in the article. These diseases are typically genetic disease with autosomal dominant and autosomal recessive type of inheritance. All diseases have common pathogenic features, such as spontaneous activation of innate immunity, maintaining of uncontrolled inflammation, absence of auto-antibodies and antigen-specific T-lymphocytes, over-secretion of interleukin-1 and good response to anti-interleukin-1 treatment. In this article you can see the basis of pathogenesis of the diseases, which determine the choice of treatment modalities and diagnostic algorhythms. Differences between clinical phenotypes of cryopyrin-associated periodic syndrome, such as familial cold urticaria (FCAS), Muckle-Wells syndrome and CINCA / NOMID syndrome are described thoroughly. You can find information about the whole group of periodic fevers and their differentiation. Data about international project «EuroFever» which can facilitate international collaboration in the fields of periodic fever are available.
About the Author
M. Gattorno
Instituto G. Gaslini, Genoa
Italy
Marco Gattorno, MD, 2nd Division of Pediatrics EULAR Centre of Excellence in Rheumatology 2008–2018 «G.Gaslini» Scientific Institute
Italy
Marco Gattorno, MD, 2nd Division of Pediatrics EULAR Centre of Excellence in Rheumatology 2008–2018 «G.Gaslini» Scientific Institute
References
1. Yalcinkaya F., Ozen S., Ozcakar Z. B., Aktay N., Cakar N., Duzova A., Kasapcopur O., Elhan A. H., Doganay B., Ekim M., Kara N., Uncu N., Bakkaloglu. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009; 48 (4): 395–398.
2. Livneh A., Langevitz P., Zemer D., Zaks N., Kees S., Lidar T., Migdal A., Padeh S., Pras M. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997; 40 (10): 1879–1885.
3. Goldfinger S. E. Colchicine for familial Mediterranean fever. N. Engl. J. Med. 1972; 287 (25): 1302.
4. Kallinich T., Haffner D., Niehues T., Huss K., Lainka E., Neudorf U., Schaefer C., Stojanov S., Timmann C., Keitzer R., Ozdogan H., Ozen S. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007; 119 (2): 474–483.
5. Frenkel J. Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology (Oxford). 2001; 40 (5): 579–584.
6. Drenth J. P. Hereditary periodic fever. N. Engl. J. Med. 2001; 345 (24): 1748–1757.
7. Hull K. M., Drewe E., Aksentijevich I., Singh H. K., Wong K., McDermott E. M., Dean J., Powell R. J., Kastner D. L. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflam matory disorder. Medicine (Baltimore). 2002; 81 (5): 349–368.
8. Toro J. R. Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch. Dermatol. 2000; 136 (12): 1487–1494.
9. Toro J. R., Aksentijevich I., Hull K. M., Dean J., Kastner D. L. Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch. Deramatol. 2000; 136 (12): 1487–1494.
10. D’Osualdo A., Ferlito F., Prigione I., Obici L., Meini A., Zulian F., Pontillo A., Corona F., Barcellona R., Di Duca M., Santamaria G., Traverso F., Picco P., Baldi M., Plebani A., Ravazzolo R., Ceccherini I., Martini A., Gattorno M. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum. 2006; 54 (3): 998–1008.
11. Siebert S., Amos N., Fielding C. A., Wang E. C., Aksentijevich I., Williams B. D., Brennan P. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis Rheum. 2005; 52 (4): 1287–1292.
12. Todd I., Radford P. M., Draper-Morgan K. A., McIntosh R., Bainbridge S., Dickinson P., Jamhawi L., Sansaridis M., Huggins M. L., Tighe P. J., Powell R. J. Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology. 2004; 113 (1): 65–79.
13. Siebert S. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-kappaB activation due to decreased surface expression. FEBS Letters. 2005; 579 (23): 5193–5198.
14. Lobito A. A., Kimberley F. C., Muppidi J. R., Komarow H., Jackson A. J., Hull K. M., Kastner D. L., Screaton G. R., Siegel R. M. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood. 2006; 108 (4): 1320–1327.
15. Gattorno M., Pelagatti M. A., Meini A., Obici L., Barcellona R., Federici S., Buoncompagni A., Plebani A., Merlini G., Martini A. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008; 58 (5): 1516–1520.
16. Ter Haar N., Lachmann H., Ozen S., Woo P., Uziel Y., Modesto C., Kone-Paut I., Cantarini L., Insalaco A., Neven B., Hofer M., Rigante D., Al-Mayouf S., Touitou I., Gallizzi R., Papadopoulou-Alataki E., Martino S., Kuemmerle-Deschner J., Obici L., Iagaru N., Simon A., Nielsen S., Martini A., Ruperto N., Gattorno M., Frenkel J. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann. Rheum. Dis. 2013; 72 (5): 678–685.
17. Blau E. B. Familial granulomatous arthritis, iritis, and rash. J. Pediatr. 1985; 107 (5): 689–693.
18. Miceli-Richard C., Lesage S., Rybojad M., Prieur A. M., Manouvrier-Hanu S., Hafner R., Chamaillard M., Zouali H., Thomas G., Hugot J. P. CARD15 mutations in Blau syndrome. Nat. Genet. 2001; 29 (1): 19–20.
19. Lindor N. M. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin. Proc. 1997; 72 (7): 611–615.
20. Wise C. A. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 2002; 11 (8): 961–969.
21. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G., Brik R., McCann L., Kasapcopur O., Rutkowska-Sak L., Schneider R., Berkun Y., Calvo I., Erguven M., Goffin L., Hofer M., Kallinich T., Oliveira S.K., Uziel Y., Viola S., Nistala K., Wouters C., Cimaz R., Ferrandiz M.A., Flato B., Gamir M.L., Kone-Paut I., Grom A., Magnusson B., Ozen S., Sztajnbok F., Lheritier K., Abrams K., Kim D., Martini A., Lovell D.J. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. New Engl. J. Med. 2012; 367; 25: 2396–2406.
Review
For citations:
Gattorno M. AUTOINFLAMMATORY DISEASES IN CHILDREN(The Lecture from 18th of September 2013, Conference «Topical Problems of Diagnostics and Treatment of Juvenile Rheumatoid Arthritis» (18–20 of September, 2013, St. Petersburg)). Current Pediatrics. 2014;13(2):55-64. (In Russ.) https://doi.org/10.15690/vsp.v13i2.973
Views:
2222
Email this article 
